Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FluLaval TF · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| FluLaval® TF | BIOLOGICAL | One IM injection. |
Inclusion Criteria: * Subjects who the investigator believes can and will comply with the requirements of the protocol * Male and female adults, 18 to 60 years of age. * Written informed consent obtained from the subject. * Satisfactory baseline medical assessment by history and physical examinatio...
FluLaval TF is an investigational vaccine being studied for the prevention of influenza. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The vaccine is being evaluated for its immunogenicity and safety in healthy adults.
FluLaval TF is being developed by GSK plc, a global biopharmaceutical company listed on the London Stock Exchange under the ticker GSK. The company is conducting clinical trials to evaluate the vaccine's safety and immune response in healthy adults.
FluLaval TF is currently in Phase 1 clinical development. It is an investigational vaccine and has not yet received regulatory approval. The Phase 1 trial has been completed, and the vaccine remains under investigation for the prevention of influenza.
FluLaval TF has one completed Phase 1 clinical trial, identified as NCT00727428. This study, titled "Immunogenicity and Safety of GSK Biologicals' FluLaval® TF," enrolled 110 healthy adults aged 18 years and older in Belgium. The trial was uncontrolled and not randomized or double-blinded.
FluLaval TF is a formulation of the influenza vaccine FluLaval, developed by GSK. The "TF" designation indicates a specific formulation being studied in clinical trials. While related to FluLaval, FluLaval TF is an investigational vaccine and has not been approved for use.